Phase 3 Clinical Trial to Evaluate of the Efficacy and Safety of DW9801 in Patients With Primary Dysmenorrhea

Inclusion Criteria: * Female patients, age between 19 years to 44years * Patients with menstrual pain over 4 out of 6 menstrual cycles before screening * Patients with moderate or severe menstrual pain for recent 2 menstrual cycles * Patients with regular menstrual cycles(28±7 days) for a year Exclusion Criteria: * Patients diagnosed or suspected of secondary dysmenorrhea * Previous adverse reaction or known allergy to NSAIDs * Breast feeding woman * Patients who are not willing to use proper contraception during clinical trial period